循環器ジャーナル66巻3号

2018年07月発行

特集 肺高血圧症Cutting Edge Ⅳ．肺高血圧症治療：内科的治療と外科的治療，そして将来の治療

プロスタサイクリン製剤—経口薬，吸入薬，皮下注薬，静注薬，何を選択し，どのように治療するのか？

著者： 大郷剛¹

所属機関： ¹国立循環器病研究センター肺循環科

ページ範囲：P.400 - P.403

Point
・プロスタサイクリン製剤は肺動脈性肺高血圧症治療薬の重要な薬剤の系統である．
・内服，吸入，皮下注，静注と様々な剤型があり，また効果も異なるため患者のコンプライアンスや病態に合った治療を行う必要がある．

参考文献

1) Rich S, Kaufmann E, Levy PS:The effect of high doses of calcium-channel blockers on survival in primary pulmonary hypertension. N Engl J Med 327:76-81, 1992

2) Humbert M, Sitbon O, Chaouat A, et al:Survival in patients with idiopathic, familial, and anorexigen-associated pulmonary arterial hypertension in the modern management era. Circulation 122:156-163, 2010

3) Moncada S, Gryglewski R, Bunting S, Vane JR:An enzyme isolated from arteries transforms prostaglandin endoperoxides to an unstable substance that inhibits platelet aggregation. Nature 263:663-665, 1976

4) Christman BW, McPherson CD, Newman JH, et al:An imbalance between the excretion of thromboxane and prostacyclin metabolites in pulmonary hypertension. N Engl J Med 327:70-75, 1992

5) Tuder RM, Cool CD, Geraci MW, et al:Prostacyclin synthase expression is decreased in lungs from patients with severe pulmonary hypertension. Am J Respir Crit Care Med 159:1925-1932, 1999

6) Nagaya N, Uematsu M, Okano Y, et al:Effect of orally active prostacyclin analogue on survival of outpatients with primary pulmonary hypertension. J Am Coll Cardiol 34:1188-1192, 1999

7) Barst RJ, McGoon M, McLaughlin V, et al:Beraprost therapy for pulmonary arterial hypertension. J Am Coll Cardiol 41:2119-2125, 2003

8) Galie N, Humbert M, Vachiery JL, et al:Effects of beraprost sodium, an oral prostacyclin analogue, in patients with pulmonary arterial hypertension:a randomized, double-blind, placebo-controlled trial. J Am Coll Cardiol 39:1496-1502, 2002

9) Kunieda T, Nakanishi N, Matsubara H, et al:Effects of long-acting beraprost sodium（TRK-100STP）in Japanese patients with pulmonary arterial hypertension. Int Heart J 50:513-529, 2009

10) Barst RJ, Rubin LJ, Long WA, et al:A comparison of continuous intravenous epoprostenol（prostacyclin）with conventional therapy for primary pulmonary hypertension. N Engl J Med 334:296-301, 1996

11) McLaughlin VV, Shillington A and Rich S. Survival in primary pulmonary hypertension:the impact of epoprostenol therapy. Circulation 106:1477-1482, 2002

12) Sitbon O, Humbert M, Nunes H, et al:Long-term intravenous epoprostenol infusion in primary pulmonary hypertension:prognostic factors and survival. J Am Coll Cardiol 40:780-788, 2002

13) Simonneau G, Barst RJ, Galie N, et al:Continuous subcutaneous infusion of treprostinil, a prostacyclin analogue, in patients with pulmonary arterial hypertension:a double-blind, randomized, placebo-controlled trial. Am J Respir Crit Care Med 165:800-804, 2002

14) Benza RL, Tapson VF, Gomberg-Maitland M, et al:One-year experience with intravenous treprostinil for pulmonary arterial hypertension. J Heart Lung Transplant 32:889-896, 2013

15) Sitbon O, Channick R, Chin KM, et al:Selexipag for the Treatment of Pulmonary Arterial Hypertension. N Engl J Med 373:2522-2533, 2015

16) Sitbon O, Jais X, Savale L, et al:Upfront triple combination therapy in pulmonary arterial hypertension:a pilot study. Eur Respir J 43:1691-1697, 2014